{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:46:47Z","timestamp":1768261607537,"version":"3.49.0"},"reference-count":39,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"vor","delay-in-days":35,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670536"],"award-info":[{"award-number":["81670536"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic hepatitis B virus (HBV) infection (CHB) in children remains a public health challenge despite significant success in programme is established to prevent mother\u2010to\u2010child transmission. In particular, CHB in Chinese children are mostly acquired through vertical transmission, which differs from the common infection route reported in other countries and regions. This situation has resulted in a high endemic prevalence of CHB in Chinese adults. Thus, successful treatment of children with CHB will prevent the development of advanced liver diseases in late adulthood. However, there is still no consensus on the clinical guideline to treat paediatric CHB. In this study, we evaluated the potential of interferon alpha (IFNa) treatment for Chinese children with CHB. A total of 41 patients with CHB aged 3\u201017\u00a0years were enrolled in this retrospective study: 21 patients were treated with pegylated (PEG)\u2010IFNa and 20 patients without treatment served as the control group. The rates of HBV DNA suppression, hepatitis B e antigen (HBeAg) clearance and hepatitis B surface antigen (HBsAg) clearance were significantly higher in the PEG\u2010IFNa treatment group than in the control group (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05 at 48\u00a0weeks). Unexpectedly, PEG\u2010IFNa treatment achieved a high rate of HBsAb production, far exceeding the clinical outcome in documented PEG\u2010IFNa\u2010treated CHB adults. Further analysis revealed that younger children (3\u20106\u00a0years old) were more responsive to PEG\u2010IFNa treatment with respect to achieving a protective level of HBsAb in a short treatment cycle than adolescents (10\u201017\u00a0years old). Overall, these results indicate that the immune system of children might have a preserved PEG\u2010IFNa\u2010mediated mechanism to completely control HBV, which can help to design new strategies to treat CHB patients.<\/jats:p>","DOI":"10.1111\/jvh.13165","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T09:30:41Z","timestamp":1564997441000},"page":"77-84","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B"],"prefix":"10.1111","volume":"26","author":[{"given":"Huimin","family":"Fan","sequence":"first","affiliation":[{"name":"Guangzhou Eighth People\u2019s Hospital Guangzhou Medical University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luping","family":"Lin","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People\u2019s Hospital Guangzhou Medical University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Jia","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People\u2019s Hospital Guangzhou Medical University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xie","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People\u2019s Hospital Guangzhou Medical University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Luo","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People\u2019s Hospital Guangzhou Medical University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghua","family":"Tan","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People\u2019s Hospital Guangzhou Medical University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruosu","family":"Ying","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People\u2019s Hospital Guangzhou Medical University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujuan","family":"Guan","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People\u2019s Hospital Guangzhou Medical University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People\u2019s Hospital Guangzhou Medical University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22962"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021410"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27406"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-017-0229-1"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcped.2016.11.009"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.12.016"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1315-4"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.02.055"},{"issue":"2","key":"e_1_2_9_10_1","first-page":"81","article-title":"Advance, challenge and strategy in control hepatitis B in China","volume":"6","author":"Fuqiang Cui HZ","year":"2016","journal-title":"Chinese J Viral Dis"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"issue":"3","key":"e_1_2_9_14_1","first-page":"37","article-title":"Pediatric hepatitis B treatment","volume":"5","author":"Komatsu H","year":"2017","journal-title":"Ann Transl Med"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308943"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.027"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i17.1919"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17701-0"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043470"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23568"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30050"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243462"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI58847"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29213"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23934"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12695"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.07.003"},{"issue":"6","key":"e_1_2_9_28_1","first-page":"636","article-title":"Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa\u20102a and a polyethylene glycol\u2010modified derivative in healthy subjects","volume":"59","author":"Nieforth KA","year":"1996","journal-title":"Clin PharmacolTher"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502061"},{"key":"e_1_2_9_30_1","unstructured":"Clinical Study Report \u2013 Protocol No. NR16141 \u2013 The safety viral kinetics and pharmacokinetics of Pegasys after multiple doses in young children with chronic hepatitis C infection \u2013 Report No. 1012174. October 2003. (CDS Vs 14.0)."},{"key":"e_1_2_9_31_1","unstructured":"GrippoJ BlotnerS.Clinical Study Report \u2013 NP17353 \u2013 Pegasys\u00ae Pharmacokinetic and Neutrophil Recovery Sub\u2010study of BV16209G Multicenter Open Label Expanded Access Program of Pegasys\u00ae (Peginterferon alfa\u20102a Ro 25\u20138310) Monotherapy and Combination Therapy with CopegusTM (Ribavirin Ro 20\u20139963) in Patients with Chronic Hepatitis C. Research No. 1019758 March 22 2006 (CDS Vs 2.0)."},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29239"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.09.006"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.07.019"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040431"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.05.031"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.03.006"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00450.x"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91371-7"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.037"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T20:00:56Z","timestamp":1694289656000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":39,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1111\/jvh.13165"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13165","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"2018-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}